The new application was based on results from the Phase III SCOUT-HCM trial.

"ASCO26: BMS and J&J debut shining multiple myeloma data" was originally created and published by Pharmaceutical Technology, ...

Arcus Biosciences has agreed to supply its investigational cancer-targeting drug to be evaluated in a Bristol Myers Squibb-sponsored trial in advanced kidney cancer. The drug, casdatifan, will be ...

Bristol Myers Squibb has high hopes for its celmod programme for blood cancers, and a phase 3 readout – for mezigdomide in ...

BMS wants AI agents inside drug discovery, clinical trials, manufacturing and corporate work. BMS will deploy Claude across more than 30 000 employees in 2026. The deal targets drug discovery, trial ...

Bristol Myers Squibb (BMS) will partner with Hengrui Pharma to co-develop 13 early-stage programs in oncology, hematology, and immunology, through a collaboration that could generate more than $15.2 ...

In the race to forge the next Keytruda from PD-(L)1xVEGF bispecific antibodies, Pfizer and the BioNTech-Bristol Myers Squibb alliance are split on how to position overall survival—the gold-standard ...

BMS will roll out Claude to over 30,000 employees, targeting three main areas for near-term impact.